Business
Johnson & Johnson Single-Shot Vaccine Safe in Trials: Report – TheStreet
Phase 1-2 trial of the Johnson & Johnson vaccine candidate generates an immune response in patients receiving the shot.
Johnson & Johnson’s (JNJ) – Get Report single-shot vaccine candidate has been shown to be safe and to generate a meaningful immune response in an early phase trial, according to a published report Wednesday.
A single shot of the vaccine “gives sustainable antibodies,” Dr. Paul Stoffels, chief scientific officer at J&J, told CNBC. The results have given the company “confidence” that the vaccine will be effective, Stoffels told CNBC.
The results of phase 1-2 trials were published Wednesday in the…
